Marc Dubin, MD
Otolaryngology · Baltimore, MDNPI 1407897770
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $256,131 of the $350,290 with a category attached, or 73.1%. Neurent Medical Limited accounts for 65.0% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $107,207, 4.9 times the $21,857 reported in 2019. Among otolaryngology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 367 payments — averaging $954.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurent Medical Limited$228K
- Medtronic$53K
- Stryker$38K
- Integra Lifesciences Corporation$20K
- Acclarent, Inc$6K
- Optinose US, Inc.$3K
- plus $3K from 6 others
Across 2 payments — averaging $9578.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurent Medical Limited$19K
What the payments were for
- Consulting fees$256,13173%
- Speaking & faculty fees$9500%
- Travel & lodging$77,11122%
- Food & beverage$13,5704%
- Education$2,5281%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurent Medical Limited | 157 | $227,713 |
| Medtronic(2 entities) | 73 | $52,898 |
| Stryker | 50 | $38,284 |
| Integra Lifesciences Corporation | 27 | $19,722 |
| Acclarent, Inc | 44 | $5,838 |
| Optinose US, Inc. | 7 | $2,827 |
| Sanofi | 2 | $2,648 |
| Intersect ENT, Inc. | 1 | $96 |
| Regeneron Healthcare Solutions, Inc. | 1 | $93 |
| Aerin Medical Inc. | 3 | $93 |
| Alk-abello, Inc | 1 | $62 |
| GSK | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROMARK Radiofrequency Console$202,761
- NEUROMARK Device$151,494
- NEUROMARK System$73,590
- NEUROMARK Radiofrequency Generator$22,323
- OMNIGRAFT$17,425
- ENTELLUS - XPRESS ENT DILATION SYSTEM$16,394
- PROPEL$14,195
- SCOPIS ENT$12,398
- XPRESS ENT DILATION SYSTEM$11,248
- STRAIGHTSHOT$10,917
- TGS GUIDEWIRE$10,555
- ENDO-SCRUB$9,821
- SHAVER SYSTEM$7,500
- ORTHOMAP$7,500
- Xhance$2,632
- TruDi$2,240
- ACCLARENT Balloon Inflation Device$2,000
- SpinPlus Navigation$2,000
- INTEGRA$1,385
- Acclarent Aera$1,376
How this compares
$350,290 in reported general payments places this provider in the 95th percentile of 222 otolaryngology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 13 | $49,091 |
| Budesonide | 24 | $13,644 |
| XhanceFluticasone Propionate | 17 | $12,328 |
| Mometasone Furoate | 16 | $4,831 |
| Ipratropium Bromide | 149 | $3,894 |
| Fluticasone Propionate | 88 | $1,321 |
| CefuroximeCefuroxime Axetil | 42 | $1,016 |
| Famotidine | 57 | $833 |
| Doxycycline Hyclate | 49 | $829 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $394 |
| Azelastine Hcl | 21 | $362 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 30 | $331 |
| Montelukast Sodium | 30 | $324 |
| Prednisone | 86 | $245 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 23 | $237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $2,827 | $12,32817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 otolaryngology providers in Maryland.
Other otolaryngology in Baltimore
- Patrick HaBaltimore$41K
- Andrew LaneBaltimore$34K
- Jean KimBaltimore$29K
- Nicholas RowanBaltimore$25K
- Rodney TaylorBaltimore$18K
- Kyle HattenBaltimore$12K
- Alexander HillelBaltimore$11K
- Carole FakhryBaltimore$11K
- Lee AkstBaltimore$10K
- Frank LinBaltimore$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.